发文分析
近年国家/地区发文量统计
| 国家/地区 | 数量 |
|---|---|
| USA | 2013 |
| GERMANY (FED REP GER) | 244 |
| CHINA MAINLAND | 243 |
| France | 193 |
| England | 186 |
| Italy | 134 |
| Canada | 124 |
| Switzerland | 116 |
| Netherlands | 115 |
| Spain | 98 |
近年机构发文量统计
| 机构 | 数量 |
|---|---|
| UNIVERSITY OF TEXAS SYSTEM | 270 |
| HARVARD UNIVERSITY | 203 |
| UNIVERSITY OF CALIFORNIA SYSTEM | 144 |
| PENNSYLVANIA COMMONWEALTH SYSTEM OF HIGHER EDU... | 115 |
| DANA-FARBER CANCER INSTITUTE | 114 |
| MEMORIAL SLOAN KETTERING CANCER CENTER | 111 |
| JOHNS HOPKINS UNIVERSITY | 108 |
| MASSACHUSETTS GENERAL HOSPITAL | 80 |
| UNICANCER | 79 |
| YALE UNIVERSITY | 79 |
近年文章引用他刊数据
| 文章名称 | 引用次数 |
|---|---|
| Cytokine release syndrome | 246 |
| Development of PD-1 and PD-L1 inhibitors as a form of ca... | 176 |
| Targeting adenosine for cancer immunotherapy | 81 |
| Immune-related adverse events and anti-tumor efficacy of... | 68 |
| A systematic review of the cost and cost-effectiveness s... | 63 |
| The role of PD-L1 expression as a predictive biomarker: ... | 62 |
| A multicenter study of body mass index in cancer patient... | 58 |
| Current landscape and future of dual anti-CTLA4 and PD-1... | 56 |
| The Society for Immunotherapy of Cancer consensus statem... | 55 |
| Updated efficacy of avelumab in patients with previously... | 53 |
近年被他刊引用数据
| 期刊名称 | 引用次数 |
|---|---|
| J IMMUNOTHER CANCER | 259 |
| FRONT IMMUNOL | 177 |
| CANCERS | 168 |
| INT J MOL SCI | 83 |
| FRONT ONCOL | 82 |
| CLIN CANCER RES | 72 |
| ONCOIMMUNOLOGY | 63 |
| IMMUNOTHERAPY-UK | 54 |
| EUR J CANCER | 44 |
| CANCER IMMUNOL IMMUN | 39 |